1,5-dichloro-2-nitro-4-propan-2-yloxybenzene

We are 1,5-dichloro-2-nitro-4-propan-2-yloxybenzene CAS:41200-97-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 41200-97-9
Product Name: 1,5-dichloro-2-nitro-4-propan-2-yloxybenzene
Other Name:
1,5-dichloro-2-nitro-4-propan-2-yloxybenzene
1,5-Dichloro-2-(1-methylethoxy)-4-nitrobenzene
2,4-Dichloro-5-nitrophenyl isopropyl ether
1,5-Dichloro-2-isopropoxy-4-nitrobenzene
 
Density: 1.4±0.1 g/cm3
Boiling Point: 338.6±37.0 °C at 760 mmHg
Molecular Formula: C9H9Cl2NO3
Molecular Weight: 250.079
Flash Point: 158.6±26.5 °C
Exact Mass: 248.995956
PSA: 55.05000
LogP: 4.14
Vapour Pressure: 0.0±0.7 mmHg at 25°C
Index of Refraction: 1.554
 
Specification
Appearance: Yellow solid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Oxadiazon CAS: 19666-30-9.
Be used as pesticide intermediate, mainly used in the synthesis of the herbicide Oxadiazon.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

1,5-dichloro-2-nitro-4-propan-2-yloxybenzene


Related News: At present, API companies basically use multi-functional and multi-purpose workshops, and the main equipment uses multi-functional reactors to achieve flexible utilization of production capacity.Iminodiacetic acid At present, API companies basically use multi-functional and multi-purpose workshops, and the main equipment uses multi-functional reactors to achieve flexible utilization of production capacity.1187595-85-2 Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.40963-14-2 Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
oleic acid View Details
2-Ethyl-6-methylaniline View Details
N-Fmoc-N’-trityl-L-histidine View Details
10-(3-(naphthalen-2-yl)phenyl)anthracene-9-boronic acid manufacturer 2′-O-methyluridine manufacturer spiro[1-azabicyclo[2.2.2]octane-3,2′-oxirane] manufacturer 1-chloro-10-iododecane manufacturer Cupric Chloride manufacturer